24
Transforming Drug Development It’s not just for researchers – you can participate! Health 2.0 New Orleans November 21, 2013 Thomas Krohn, RPh, MBA Eli Lilly and Company

Transforming Drug Development at Lilly

Embed Size (px)

Citation preview

Page 1: Transforming Drug Development at Lilly

Transforming Drug Development It’s not just for researchers – you can participate!

Health 2.0 New Orleans November 21, 2013 Thomas Krohn, RPh, MBA Eli Lilly and Company

Page 2: Transforming Drug Development at Lilly

Drug Development - today

Precompetitive Competitive patent

Innovation Process

Page 3: Transforming Drug Development at Lilly

Business Model Performance

Source: FDA.gov

Productivity Down, Costs Up Future revenues under pressure

Unsustainable Business Model

Page 4: Transforming Drug Development at Lilly

Moore’s vs. Eroom’s Law

Page 5: Transforming Drug Development at Lilly

The Far Side by Gary Larson

Page 6: Transforming Drug Development at Lilly

Incremental Improvement

Page 7: Transforming Drug Development at Lilly
Page 8: Transforming Drug Development at Lilly

Disruptive Innovation

to S1'

to S2

S1

Time

Per

form

ance

Disruptive Change

Simpler, Faster, Cheaper?

Page 9: Transforming Drug Development at Lilly

Disruption in motion

Page 10: Transforming Drug Development at Lilly

Generation and Access to Data

Page 11: Transforming Drug Development at Lilly

Patient Digital Monitoring

Page 12: Transforming Drug Development at Lilly

Patient Communities

Patients as microexperts – not subjects

Page 13: Transforming Drug Development at Lilly

Patient-Driven Research

Page 14: Transforming Drug Development at Lilly

The Disruption

Power to the Patient

Page 15: Transforming Drug Development at Lilly

Clinical Research as part of Healthcare

Public Perception •  94% of people recognize the importance of participating in clinical research

in order to assist in the advancement of medical science. Yet 75% of the general public state they have little to no knowledge about the clinical research enterprise and the participation process. (www.centerwatch.com)

•  Less than five percent of cancer patients participate in clinical trials. If ten percent participated, studies could be completed in one year, instead of the three-five years that studies currently require. (National Cancer Institute)

•  It's not uncommon for your cancer doctor or treatment team to discuss the option of a clinical trial as the best treatment choice for your cancer type. (www.mayoclinic.com)

Standard of Care Clinical Trial Info & Innovation

Page 16: Transforming Drug Development at Lilly

ClinicalTrials.Gov and Patients

98,000,000 Pageviews/Month1

Sources: 1) clinicaltrials.gov site 2) D. Zarin 2007 Overview

47,000,000 Patient driven pageviews/Month

2

What if….?

Page 17: Transforming Drug Development at Lilly

1

Patient-Centric Design

Patient Voice

2

Patient-Centric Study Representation & Voice

Study Representation

Informed Consent Document Ct.Gov

Study Design

Open

Platform

Patients

• Clear eligibility • Risk/Benefit • My doctor’s role • Study treatment • Time to results • Logistics

Design Challenge

ctdesign.challengepost.com

November 14

Page 18: Transforming Drug Development at Lilly

Patient-Centric Information

Open

Platform

Patients

labs.lillycoi.com

Page 19: Transforming Drug Development at Lilly

Clinical Open Innovation

Open

Platform

Patients

api.lillycoi.com

Daily Updates

Open Web

REST API

Page 20: Transforming Drug Development at Lilly

Enabling patient matching to studies

Open

Platform

Patients

api.lillycoi.com

Daily Updates

Open Web

REST API

Patient Study “Target Profiles”

Study Sponsors

Patient & Communities

Personal Electronic Medical Records

Match Process

Consent to

Match

Page 21: Transforming Drug Development at Lilly

Patient Engagement App Challenge

http://patientengagement.challengepost.com

Page 22: Transforming Drug Development at Lilly

Join the transformation

•  Learn the business model •  Understand patient needs •  Identify options for value creation •  Explore open data and patient engagement •  Participate in challenges

Most people are afraid of making mistakes. Leaders are afraid of missing opportunities.

Page 23: Transforming Drug Development at Lilly

References

•  Website: www.lillycoi.com •  API: api.lillycoi.com •  App Lab: labs.lillycoi.com •  Whitepaper: link •  Twitter: @Lilly_COI, @takmad

Page 24: Transforming Drug Development at Lilly

Thanks!